Targeting IL-1β signaling, either genetically or pharmacologically using the neutralizing IL-1β antibody canakinumab or the IL1R antagonist Anakinra, significantly reduced experimental BrCa and PrCa bone metastases [154,157,162,163]. The gene discussed is IL1B; the disease is invasive breast carcinoma.